

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Nintedanib for treating idiopathic pulmonary fibrosis
in people with a forced vital capacity above 80% predicted
(part-review of technology appraisal guidance 379)
[ID4062]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final Draft Guidance

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

At scoping consultation, 1 consultee commented that a negative outcome will result in an inequality of access to treatment for patients above FVC 80% in IPF as nintedanib is currently available for other progressive fibrotic diseases. However, this is not an equality or diversity issue which needed to be addressed in the scope.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

Multiple experts and patient groups commented that a negative outcome will result in an inequality of access to treatment for patients above FVC 80% predicted. Some commenters noted this may impact elderly people more, as FVC tends to be less reliable in elderly people. Nintedanib received a positive recommendation so issues of access inequality in the case of a
--

negative recommendation were not relevant, however the general reliability of FVC as a measure of severity of IPF was discussed.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Section 3.10

Approved by Associate Director (name): ...Linda Landells.....

Date: 31 January 2023